Quick Answer
Sagimet Biosciences Inc. reported R&D Expense of $39.05 million for fiscal year 2025.
Sagimet Biosciences Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $39.05M | +1.6% |
| 2024 | $38.44M | +94.4% |
| 2023 | $19.78M | -20.6% |
| 2022 | $24.92M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.73M | -23.1% | +34.2% |
| June 30, 2025 | $7.25M | +14.8% | -52.8% |
| March 31, 2025 | $15.34M | +191.6% | +21.3% |
| September 30, 2024 | $12.65M | +155.2% | +100.4% |
| June 30, 2024 | $6.31M | +35.0% | +20.0% |
| March 31, 2024 | $5.26M | +17.3% | +6.1% |
| September 30, 2023 | $4.96M | -27.5% | +6.0% |
| June 30, 2023 | $4.68M | -26.6% | +4.2% |
- Sagimet Biosciences Inc. showed an increase of +1.6% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Sagimet Biosciences Inc.’s r&d expense has grown by 56.7% (from $24.92 million to $39.05 million).
- The most recent figure is from Sagimet Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: